Prognostic Role of Conversion Surgery for Unresectable Gastric Cancer

[1]  X. Qin,et al.  A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis , 2014, Cancer Chemotherapy and Pharmacology.

[2]  A. Nashimoto,et al.  Phase II study of preoperative chemotherapy with S‐1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210) , 2013, Journal of surgical oncology.

[3]  H. Kuwano,et al.  Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer , 2012, British Journal of Cancer.

[4]  Y. Kodera,et al.  Long-term follow up of patients who were positive for peritoneal lavage cytology: final report from the CCOG0301 study , 2012, Gastric Cancer.

[5]  S. Osada,et al.  The Roles of Surgical Oncologists in the New Era – Minimally Invasive Surgery for Early Gastric Cancer and Adjuvant Surgery for Metastatic Gastric Cancer , 2011, Pathobiology.

[6]  H. Ohdan,et al.  Preliminary trial of adjuvant surgery for advanced gastric cancer. , 2010, Oncology letters.

[7]  K. Obama,et al.  Induction Chemotherapy with S-1 Plus Cisplatin Followed by Surgery for Treatment of Gastric Cancer with Peritoneal Dissemination , 2009, Annals of surgical oncology.

[8]  Masahiro Takeuchi,et al.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. , 2008, The Lancet. Oncology.

[9]  D. Cunningham,et al.  The UK NCRI MAGIC Trial of Perioperative Chemotherapy in Resectable Gastric Cancer: Implications for Clinical Practice , 2007, Annals of surgical oncology.

[10]  A. Neugut,et al.  Epidemiology of gastric cancer. , 2006, World journal of gastroenterology.

[11]  A. Ohtsu,et al.  Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer , 2003, British Journal of Cancer.

[12]  A. Yanagisawa,et al.  Combined intensive chemotherapy and radical surgery for incurable gastric cancer , 1997, Annals of Surgical Oncology.

[13]  T. Hickish,et al.  A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  C. Gisselbrecht,et al.  5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. , 1980, Annals of internal medicine.

[15]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[16]  Leslie H. Sobin,et al.  TNM Classification of Malignant Tumours, 7th Edition , 2009 .

[17]  S. Yoshida,et al.  Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.